{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:18:25Z","timestamp":1783019905429,"version":"3.54.6"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2010-2314841"],"award-info":[{"award-number":["RF-2010-2314841"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00259-019-04323-6","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T09:15:39Z","timestamp":1558084539000},"page":"1661-1671","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Role of 18F-FLT PET\/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6784-8220","authenticated-orcid":false,"given":"Lucia","family":"Zanoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Broccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Stefoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Lodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Fonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Nanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,17]]},"reference":[{"key":"4323_CR1","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1053\/j.semnuclmed.2007.01.001","volume":"37","author":"U Metser","year":"2007","unstructured":"Metser U, Even-Sapir E. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography\/computed tomography (PET\/CT): accumulated data from four years of experience with PET\/CT. Semin Nucl Med. 2007;37:206\u201322.","journal-title":"Semin Nucl Med"},{"key":"4323_CR2","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/01.mph.0000212912.37512.b1","volume":"28","author":"MM Rhodes","year":"2006","unstructured":"Rhodes MM, Delbeke D, Whitlock JA, et al. Utility of FDG-PET\/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol. 2006;28:300\u20136.","journal-title":"J Pediatr Hematol Oncol"},{"key":"4323_CR3","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/ajh.23423","volume":"88","author":"I Avivi","year":"2013","unstructured":"Avivi I, Zilberlicht A, Dann EJ, et al. Strikingly high false positivity of surveillance FDG-PET\/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. Am J Hematol. 2013;88:400\u20135.","journal-title":"Am J Hematol"},{"key":"4323_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/annonc\/mdn629","volume":"20","author":"HS Han","year":"2009","unstructured":"Han HS, Escalon MP, Hsiao B, et al. High incidence of false- positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituxi-mab-containing regimens. Ann Oncol. 2009;20:309\u201318.","journal-title":"Ann Oncol"},{"key":"4323_CR5","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3109\/10428194.2010.547642","volume":"52","author":"T El-Galaly","year":"2011","unstructured":"El-Galaly T, Prakash V, Christiansen I, et al. Efficacy of routine surveillance with positron emission tomography\/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center. Leuk Lymphoma. 2011;52:597\u2013603.","journal-title":"Leuk Lymphoma"},{"key":"4323_CR6","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1200\/JCO.2008.16.1513","volume":"27","author":"PL Zinzani","year":"2009","unstructured":"Zinzani PL, Stefoni V, Tani M, et al. Role of [F-18]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol. 2009;27:1781\u20137.","journal-title":"J Clin Oncol"},{"key":"4323_CR7","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3324\/haematol.10798","volume":"92","author":"PL Zinzani","year":"2007","unstructured":"Zinzani PL, Tani M, Trisolini R, et al. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. Haematologica. 2007;92:771\u20137.","journal-title":"Haematologica"},{"key":"4323_CR8","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/3337","volume":"4","author":"AF Shields","year":"1998","unstructured":"Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334\u20136.","journal-title":"Nat Med"},{"key":"4323_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.canlet.2011.10.025","volume":"316","author":"S Aufderklamm","year":"2012","unstructured":"Aufderklamm S, Todenh\u00f6fer T, Gakis G, et al. Thymidine kinase and cancer monitoring. Cancer Lett. 2012;316:6\u201310.","journal-title":"Cancer Lett"},{"key":"4323_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0969-8051(02)00286-X","volume":"29","author":"J Toyohara","year":"2002","unstructured":"Toyohara J, Waki A, Takamatsu S, et al. Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol. 2002;29:281\u20137.","journal-title":"Nucl Med Biol"},{"key":"4323_CR11","first-page":"1210","volume":"43","author":"JS Rasey","year":"2002","unstructured":"Rasey JS, Grierson JR, Wiens LW, et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210\u20137.","journal-title":"J Nucl Med"},{"key":"4323_CR12","first-page":"2027","volume":"44","author":"JL Schwartz","year":"2003","unstructured":"Schwartz JL, Tamura Y, Jordan R, et al. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med. 2003;44:2027\u201332.","journal-title":"J Nucl Med"},{"key":"4323_CR13","first-page":"3791","volume":"63","author":"H Barthel","year":"2003","unstructured":"Barthel H, Cleij MC, Collingridge DR, et al. 3-Deoxy-3-[18F] fluorothymidine as a new marker for monitoring tumor response to anti- proliferative therapy in vivo with positron emission tomography. Cancer Res. 2003;63:3791\u20138.","journal-title":"Cancer Res"},{"key":"4323_CR14","doi-asserted-by":"publisher","first-page":"11055","DOI":"10.1158\/0008-5472.CAN-06-1955","volume":"66","author":"AK Buck","year":"2006","unstructured":"Buck AK, Bommer M, Stilgenbauer S, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res. 2006;66:11055\u201361.","journal-title":"Cancer Res"},{"key":"4323_CR15","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ejca.2011.11.035","volume":"48","author":"D Soloviev","year":"2012","unstructured":"Soloviev D, Lewis D, Honess D, et al. [18F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment. Eur J Cancer. 2012;48:416\u201324.","journal-title":"Eur J Cancer"},{"key":"4323_CR16","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.2174\/138161208786549399","volume":"14","author":"A van Waarde","year":"2008","unstructured":"van Waarde A, Elsinga PH. Proliferation markers for the differential diagnosis of tumor and inflammation. Curr Pharm Des. 2008;14:3326\u201339.","journal-title":"Curr Pharm Des"},{"key":"4323_CR17","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1097\/MNM.0b013e32832ee93b","volume":"30","author":"T Barwick","year":"2009","unstructured":"Barwick T, Bencherif B, Mountz JM, et al. Molecular PET and PET\/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Nucl Med Commun. 2009;30:908\u201317.","journal-title":"Nucl Med Commun"},{"key":"4323_CR18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/hon.2093","volume":"32","author":"R Wang","year":"2014","unstructured":"Wang R, Zhu H, Chen Y, et al. Standardized uptake value based evaluation of lymphoma by FDG and FLT PET\/CT. Hematol Oncol. 2014;32:126\u201332.","journal-title":"Hematol Oncol"},{"key":"4323_CR19","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2967\/jnumed.114.149625","volume":"56","author":"MJ Wondergem","year":"2015","unstructured":"Wondergem MJ, Rizvi SNF, Jauw Y, et al. 18F-FDG or 3\u2032-Deoxy-3\u2032- 18F-Fluorothymidine to detect transformation of follicular lymphoma. J Nucl Med. 2015;56:216\u201321.","journal-title":"J Nucl Med"},{"key":"4323_CR20","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1080\/10428190601113568","volume":"48","author":"B Kasper","year":"2007","unstructured":"Kasper B, Egerer G, Gronkowski M, et al. Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. Leuk Lymphoma. 2007;48:746\u201353.","journal-title":"Leuk Lymphoma"},{"key":"4323_CR21","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1158\/1078-0432.CCR-06-3025","volume":"13","author":"K Herrmann","year":"2007","unstructured":"Herrmann K, Wieder HA, Buck AK, et al. Early response assessment using 3\u2032-deoxy-3\u2032-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res. 2007;13:3552\u20138.","journal-title":"Clin Cancer Res"},{"key":"4323_CR22","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1097\/RLU.0000000000000539","volume":"39","author":"E Mena","year":"2014","unstructured":"Mena E, Lindenberg ML, Turkbey BI, et al. A pilot study of the value of 18F-Fluoro-deoxy-thymidine PET\/CT in predicting viable lymphoma in residual 18F-FDG avid masses after completion of therapy. Clin Nucl Med. 2014;39:874\u201381.","journal-title":"Clin Nucl Med"},{"key":"4323_CR23","doi-asserted-by":"publisher","first-page":"690","DOI":"10.2967\/jnumed.110.084566","volume":"52","author":"K Herrmann","year":"2011","unstructured":"Herrmann K, Buck AK, Schuster T, et al. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. J Nucl Med. 2011;52:690\u20136.","journal-title":"J Nucl Med"},{"key":"4323_CR24","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.2967\/jnumed.111.094698","volume":"52","author":"K Herrmann","year":"2011","unstructured":"Herrmann K, Buck AK, Schuster T, et al. A pilot study to evaluate 3\u2032-Deoxy-3'-18F-Fluorothymidine PET for initial and early response imaging in mantle cell lymphoma. J Nucl Med. 2011;52:1898\u2013902.","journal-title":"J Nucl Med"},{"key":"4323_CR25","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4323_CR26","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1200\/JCO.1990.8.9.1602","volume":"8","author":"TA Lister","year":"1990","unstructured":"Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1990;8:1602.","journal-title":"J Clin Oncol"},{"key":"4323_CR27","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1200\/JCO.1990.8.9.1598","volume":"8","author":"CL Olweny","year":"1990","unstructured":"Olweny CL. Cotswolds modification of the Ann Arbor staging system for Hodgkin's disease. J Clin Oncol. 1990;8:1598.","journal-title":"J Clin Oncol"},{"key":"4323_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12149-015-1047-6","volume":"30","author":"SJ Rayamajhi","year":"2016","unstructured":"Rayamajhi SJ, Mittal BR, Maturu VN, et al. 18F-FDG and 18F-FLT PET\/CT imaging in the characterization of mediastinal lymph nodes. Ann Nucl Med. 2016;30:207\u201316.","journal-title":"Ann Nucl Med"},{"key":"4323_CR29","doi-asserted-by":"publisher","first-page":"726","DOI":"10.2967\/jnumed.106.037473","volume":"48","author":"EGC Troost","year":"2007","unstructured":"Troost EGC, Vogel WV, Merkx MAW, et al. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med. 2007;48:726\u201335.","journal-title":"J Nucl Med"},{"key":"4323_CR30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejca.2015.11.018","volume":"55","author":"VR Bollineni","year":"2016","unstructured":"Bollineni VR, Kramer GM, Jansma EP, et al. A systematic review on [18F]FLT-PET uptake as a measure of treatment response in cancer patients. Eur J Cancer. 2016;55:81\u201397.","journal-title":"Eur J Cancer"},{"key":"4323_CR31","doi-asserted-by":"publisher","first-page":"728","DOI":"10.2967\/jnumed.115.166769","volume":"57","author":"H Sch\u00f6der","year":"2016","unstructured":"Sch\u00f6der H, Zelenetz AD, Hamlin P, et al. Prospective study of 3\u2032-Deoxy-3'-18F-Fluorothymidine PET for early interim response assessment in advanced-stage B-cell lymphoma. J Nucl Med. 2016;57:728\u201334.","journal-title":"J Nucl Med"},{"key":"4323_CR32","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2967\/jnumed.113.124172","volume":"55","author":"H Lee","year":"2014","unstructured":"Lee H, Kim SK, Kim YI, et al. Early determination of prognosis by interim 3\u2032-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma. J Nucl Med. 2014;55:216\u201322.","journal-title":"J Nucl Med"},{"key":"4323_CR33","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1148\/radiol.2015150689","volume":"280","author":"R Minamimoto","year":"2016","unstructured":"Minamimoto R, Fayad L, Advani R, et al. Diffuse large B-cell lymphoma: prospective multicenter comparison of early interim FLT PET\/CT versus FDG PET\/CT with IHP, EORTC, Deauville, and PERCIST criteria for early therapeutic monitoring. Radiology. 2016;280:220\u20139.","journal-title":"Radiology"},{"key":"4323_CR34","first-page":"1482","volume":"44","author":"H Vesselle","year":"2003","unstructured":"Vesselle H, Grierson J, Peterson LM, et al. 18F-Fluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med. 2003;44:1482\u20138.","journal-title":"J Nucl Med"},{"key":"4323_CR35","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1016\/j.ejca.2012.05.001","volume":"48","author":"A Chalkidou","year":"2012","unstructured":"Chalkidou A, Landau DB, Odell EW, et al. Correlation between Ki- 67 immunohistochemistry and 18F-Fluorothymidine uptake in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2012;48:3499\u2013513.","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04323-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-019-04323-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04323-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T23:37:09Z","timestamp":1589585829000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-019-04323-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,17]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["4323"],"URL":"https:\/\/doi.org\/10.1007\/s00259-019-04323-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,17]]},"assertion":[{"value":"6 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.Local Ethical Committee code: 77\/2009\/O\/Sper.EudraCT Number 2009-012561-56.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}